[Alternative measures for patients with chronic hepatitis C unresponsive to interferon therapy].
Imazeki
Fumio
F
Department of Medicine and Clinical Oncology, Graduate School of Medicine, Chiba University.
D000998:Antiviral Agents / Q000008:administration & dosage*; D006528:Carcinoma, Hepatocellular / Q000209:etiology / Q000517:prevention & control; D002986:Clinical Trials as Topic; D003545:Cysteine / Q000627:therapeutic use; D004338:Drug Combinations; D004359:Drug Therapy, Combination; D005838:Genotype; D005998:Glycine / Q000627:therapeutic use; D016174:Hepacivirus / Q000235:genetics; D019698:Hepatitis C, Chronic / Q000150:complications / Q000628:therapy* / Q000821:virology; D006801:Humans; D007372:Interferons / Q000008:administration & dosage*; D019266:Iron, Dietary / Q000008:administration & dosage; D008113:Liver Neoplasms / Q000209:etiology / Q000517:prevention & control; D009828:Oleanolic Acid / Q000031:analogs & derivatives* / Q000627:therapeutic use; D018962:Phlebotomy; D011379:Prognosis; D012254:Ribavirin / Q000008:administration & dosage; D013997:Time Factors
D000998:Antiviral Agents; D004338:Drug Combinations; D019266:Iron, Dietary; D012254:Ribavirin; D009828:Oleanolic Acid; C009781:neominophagen C; D007372:Interferons; D003545:Cysteine; D005998:Glycine